S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

HSBC Sheds Singapore Insurance Unit in $2.1 Billion Allianz Deal

After a failed attempt to acquire Income Insurance earlier this year, Allianz has secured a major foothold in Singapore by purchasing HSBC’s life and health insurance business for S$2.7 billion. The transaction marks a strategic pivot for the British lender as it seeks to streamline operations across its core Asian markets.

HSBC Sheds Singapore Insurance Unit in $2.1 Billion Allianz Deal
Photo: Business Person

The deal, slated for completion in the first half of 2027, will see HSBC transition to a capital-light bancassurance model. By offloading its underwriting obligations, the bank expects to generate a pre-tax gain of $1.8 billion and improve its common equity tier 1 ratio by up to 15 basis points. CEO Georges Elhedery continues to prune non-core assets to focus on wealth and wholesale banking, a strategy that has already prompted reviews of retail businesses in Australia, Turkey, and Egypt.

For Allianz, the agreement provides a critical entry point into one of Asia’s most lucrative wealth management hubs. Following the sale, HSBC will distribute Allianz products in Singapore for a minimum of 15 years, supported by an upfront payment of S$200 million. While HSBC’s Hong Kong-listed shares dipped 1.1% following the announcement, analysts suggest the freed-up capital could bolster the bank's capacity for share buybacks or investments in higher-growth areas like private credit.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!